🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

US Medicare issues updated rules for second round of drug negotiations

Published 10/02/2024, 05:43 PM
Updated 10/02/2024, 05:47 PM
© Reuters. FILE PHOTO: U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File photo

By Ahmed Aboulenein

WASHINGTON (Reuters) - The U.S. government will provide more time for negotiations and more chances for drugmakers to submit counter offers during the second round of talks over price cuts for its Medicare program, it said on Wednesday.

WHY IT'S IMPORTANT

The Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, the government health insurance program for millions of Americans age 65 and older and the disabled, by Feb. 1 will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.

The guidance is being closely watched by pharmaceutical manufacturers who make the 15 drugs likely to get picked for negotiations.

CMS said changes to the process, which came after feedback from patients and drugmakers, include meeting with companies earlier in the process and allowing more opportunities for counter offers.

The agency will now meet with drugmakers before making its initial offer, and will hold one of the three allotted negotiation meetings before the deadline for the first counter offer. If a company chooses to counter the government's offer, it will have two further meetings to negotiate.

KEY QUOTES

"What we plan to do is have meetings with manufacturers before CMS actually sends an initial offer. But then once we have done an initial offer, we will have a first optional negotiation meeting with the manufacturer earlier than we did this past year," a CMS official told reporters on a press call.

"That will provide us with an opportunity to have a dialogue about the initial offer that CMS has sent, and potentially some early thinking from the manufacturer themselves around how they might do a counteroffer."

CONTEXT

© Reuters. FILE PHOTO: U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File photo

CMS announced prices for ten drugs in August in its first round of cuts following a year of talks. The prices are set to take effect in January 2026 and will save older Americans $1.5 billion in out of pocket costs, according to the agency.

Next year's talks will take place in a shorter timeframe, with a final decision on prices due by Nov. 30, 2025.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.